A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)

Background: Induction chemotherapy (IC) is a treatment option for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). However, treatment with docetaxel, cisplatin, and 5-FU (TPF) followed by cisplatin and radiotherapy is controversial because of toxicity concerns. The aim of th...

Full description

Bibliographic Details
Main Authors: Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka, Makoto Tahara
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Oncology
Subjects:
head and neck cancer
induction chemotherapy
cetuximab
clinical trial
endpoint
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00006/full

Similar Items

Similar Items